• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

ZyPREXA (olanzapine)

Audience: Neuropsychiatric healthcare professionals and pharmacists

Eli Lilly and FDA notified healthcare professionals reports of medication dispensing or prescribing errors between the atypical antipsychotic ZyPREXA (olanzapine), indicated for the short-term and maintenance treatment of schizophrenia and for the short-term treatment of acute mixed or manic episodes associated with Bipolar I Disorder, and the antihistamine ZYRTEC (cetirizine HCI) marketed by Pfizer, indicated for the treatment of allergic rhinitis or chronic urticaria. These reports include instances where Zyprexa was incorrectly dispensed for Zyrtec and vice versa, leading to unnecessary adverse events or potential relapse in patients suffering from schizophrenia or bipolar disorder.

[January 26, 2005 - Letter - Eli Lilly]